Immunochromatographic Strip Endorsed for α-Thalassemia Screening
|
By LabMedica International staff writers Posted on 19 Nov 2014 |

Image: Immunochromatographic strip test for Hb Bart’s in blood samples of α0-thalassemia heterozygote and individuals double heterozygous for homozygous Hb E and α0-thalassemia and α0β-thalassemia double heterozygote (Photo courtesy of Mahidol University).

Image: Inclusion body positive cells seen in Brilliant Cresyl Blue stained red cells of a α0-thalassaemia carrier (Photo courtesy of American Society of Hematology).
Thalassemia is an autosomal recessive inherited genetic disorder of the red blood cells causing by reduction or absence of one or more globin chains of hemoglobin (Hb) molecules.
An immunochromatographic (IC) strip test has been developed for rapid screening of α0-thalassemia by testing for Hb Bart’s in blood samples using a specific monoclonal antibody against Hb Bart's.
Molecular Bioscientists at the Mahidol University, Nakhonpathom, Thailand) working with their Australian colleagues, collected a total of 662 routinely leftover anticoagulated blood samples, 411 from Thailand and 251from West Australia and included in a multicenter study. Hematologic data were determined by the automatic blood cell counters being operated at individuals laboratory collaborated in this multicenter study.
Polymerase chain reaction (PCR) was used to identify α0-thalassemia, α+-thalassemia, Hb H disease and non-deletion α-thalassemia in most samples. In two laboratories α-thalassemias were detected by the presence of erythrocyte Hb H inclusion bodies using the enriched young red cells from just below the buffy coat. A modified Alpha Thal IC strip test (i+MED Laboratories, Bangkok, Thailand) for screening of α-thalassemia was also tested.
There were 45 samples with α-thalassemia traits and were demonstrated to have the α0-thalassemia gene, 18 were from Hb H and EA Bart’s disease patients and 15 were homozygous α+-thalassemia or compound heterozygous α+-thalassemia and non-deletion α-thalassemia. All of these samples showed strongly positive results with IC strip test except for two α0-thalassemia samples, which had the negative results and were accounted for as false negatives. Among the 180 samples with normal α-globin genotyping the IC strip test revealed 97.8% negative reactivity.
The authors concluded that in combination with red blood cell indices, the IC strip test could rule out mass populations for further α0-thalassemia detection by PCR-based analysis. The established IC strip test has an advantage since it does not require sophisticated equipment, easy to perform and the result can be visually interpreted without an expert. It is also less-time consuming and can be done with a large number of samples, and therefore the IC strip test can be applied in thalassemia screening program, which will reduce the need of expensive PCR methods in the inappropriate cases for diagnosis of α0-thalassemia carriers. The study was published on November 6, 2014, in the journal Translational Research.
Related Links:
Mahidol University
i+MED Laboratories
An immunochromatographic (IC) strip test has been developed for rapid screening of α0-thalassemia by testing for Hb Bart’s in blood samples using a specific monoclonal antibody against Hb Bart's.
Molecular Bioscientists at the Mahidol University, Nakhonpathom, Thailand) working with their Australian colleagues, collected a total of 662 routinely leftover anticoagulated blood samples, 411 from Thailand and 251from West Australia and included in a multicenter study. Hematologic data were determined by the automatic blood cell counters being operated at individuals laboratory collaborated in this multicenter study.
Polymerase chain reaction (PCR) was used to identify α0-thalassemia, α+-thalassemia, Hb H disease and non-deletion α-thalassemia in most samples. In two laboratories α-thalassemias were detected by the presence of erythrocyte Hb H inclusion bodies using the enriched young red cells from just below the buffy coat. A modified Alpha Thal IC strip test (i+MED Laboratories, Bangkok, Thailand) for screening of α-thalassemia was also tested.
There were 45 samples with α-thalassemia traits and were demonstrated to have the α0-thalassemia gene, 18 were from Hb H and EA Bart’s disease patients and 15 were homozygous α+-thalassemia or compound heterozygous α+-thalassemia and non-deletion α-thalassemia. All of these samples showed strongly positive results with IC strip test except for two α0-thalassemia samples, which had the negative results and were accounted for as false negatives. Among the 180 samples with normal α-globin genotyping the IC strip test revealed 97.8% negative reactivity.
The authors concluded that in combination with red blood cell indices, the IC strip test could rule out mass populations for further α0-thalassemia detection by PCR-based analysis. The established IC strip test has an advantage since it does not require sophisticated equipment, easy to perform and the result can be visually interpreted without an expert. It is also less-time consuming and can be done with a large number of samples, and therefore the IC strip test can be applied in thalassemia screening program, which will reduce the need of expensive PCR methods in the inappropriate cases for diagnosis of α0-thalassemia carriers. The study was published on November 6, 2014, in the journal Translational Research.
Related Links:
Mahidol University
i+MED Laboratories
Latest Hematology News
- New Guidelines Aim to Improve AL Amyloidosis Diagnosis
- Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
- Fast and Easy Test Could Revolutionize Blood Transfusions
- High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
- AI Algorithm Effectively Distinguishes Alpha Thalassemia Subtypes
- MRD Tests Could Predict Survival in Leukemia Patients
- Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
- Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
- ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
- Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
- Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
- Platelets Could Improve Early and Minimally Invasive Detection of Cancer
- Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment
- Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
- First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes

- New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







